TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05091450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based I-BMS intervention for infertility
Description: It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couple-based I-BMS intervention for infertility
Description: It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
Study: NCT04791020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain topical + paracervical blockade
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
Study: NCT06577948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision spectacle lens
Description: Standard single vision spectacle lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.A.U.S.E. spectacle lens 1
Description: P.A.U.S.E. spectacle lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.A.U.S.E. spectacle lens 2
Description: P.A.U.S.E. spectacle lens 2
Study: NCT06554899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician-led intervention to address fear of cancer recurrence (CIFeR)
Description: The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF \>= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
Study: NCT06573242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation for people living with Heart Failure and their caregivers
Description: Intervention DK:REACH-HF is a home-based 12-week CR program for people living with HF and their caregivers.
Study: NCT06641258

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (Standard Procedure)
Description: Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied
Study: NCT06535893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TN
Description: Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-1
Description: Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
Study: NCT06019832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Description: Both study arms will undergo TKA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Description: Both study arms will undergo TKA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemmed Tibial Implant
Description: A stemmed tibial implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-stemmed tibial implant
Description: non-stemmed tibial implants
Study: NCT05378763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Poziotinib tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel IV infusion
Study: NCT06420063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123/CD33 CART
Description: The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses.
Study: NCT06026332

Intervention type: DRUG
Intervention: ADSTILADRIN
Description: Non-interventional
Study: NCT06284564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Given by SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study: NCT05363215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration
Study: NCT05802875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RASMUS Resilience Training
Description: RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS.
Study: NCT05023876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM+respiratory Exercise
Description: Instrument assisted soft tissue mobilization
Study: NCT06234475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health support
Description: 1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: 1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combine intervention
Description: 1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~7. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: 1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~6. Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending
Study: NCT04309500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized DAT Risk Disclosure Protocol
Description: Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized DAT Risk Disclosure Protocol
Description: Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized DAT Risk Disclosure Protocol
Description: Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized DAT Risk Disclosure Protocol
Description: Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
Study: NCT05023876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Exercise
Description: Respiratory Exercise
Study: NCT06643026

Intervention type: OTHER
Intervention: Food preference
Description: Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.

Intervention type: OTHER
Intervention: Food preference
Description: Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.
Study: NCT06638268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute TAVI
Description: TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization and subacute TAVI
Description: Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
Study: NCT06426719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge wideninig via applying osseodensification protocol using densah burs
Description: alveolar ridge expansion using densah burs in horizontally deficient maxillary alveolar ridges prior to dental implants insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge widening via hand osteotomes
Description: Alveolar ridge expansion using hand driven osteotomes in horizontally deficient maxillary alveolar ridges prior to dental Implant insertion
Study: NCT05391451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery
Description: no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
Study: NCT05519878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo routine treatment and usual follow up care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Undergo bright white therapy
Study: NCT05150405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF31907
Description: In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
Study: NCT05790460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
Study: NCT06599619

Intervention type: DRUG
Intervention: Nivolumab
Description: Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.
Study: NCT05519878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Undergo bright white therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Undergo occupational therapy
Study: NCT06256939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy BRIDGE Program
Description: A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
Study: NCT05519878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Undergo occupational therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05409183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD-740
Description: Tablets administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally.
Study: NCT05776381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making using a Patient Decision Aid.
Description: The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
Study: NCT06645028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive treatment programme
Description: Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule:~Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
Study: NCT05212337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Subcutaneous injection with 60 mg Denosumab once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Subcutaneous injection with NaCl once